Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline
Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline.
Mentions
Extended reach
Total likes
Video views
Mentions per month
Sep 2023 – May 2025Where it's discussed
-
X / Twitter118 posts
-
YouTube2 videos
AI synopsis
What people are saying
Numerous discussions highlight the importance of the ASCO guidelines, with comments such as 'honored to have contributed' and 'truly grateful to be part of the first ASCO guideline.' Contributors often use encouraging language to convey their enthusiasm, stating this work will greatly aid in the management of NETs. The tone across the discussions is celebratory and cooperative, indicating a shared belief in the potential impact of the guidelines on patient care.
The overwhelming majority of discussions express strong support for the guidelines.
The posts showcase a high level of curiosity and importance regarding the guidelines.
Many contributors reference specific aspects of the recommendations and express gratitude for the collaborative effort.
Users perceive the guidelines as having a significant effect on treatment practices for neuroendocrine tumors.
Abstract in brief
- The purpose of the study was to create guidelines for treating metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) from grade 1 to grade 3.
- The review identified eight clinical trials that helped inform these treatment recommendations, backed by an expert panel from ASCO.
- Key recommendations include using somatostatin analogs (SSAs) as the first-line therapy for many patients, considering observation for low-risk cases, and prescribing peptide receptor radionuclide therapy (PRRT) or everolimus as second-line options based on tumor characteristics.
Top posts
Most liked on X and BlueskyTruly grateful to be part of the first ASCO guideline for the management of NETs and everyone involved! Thank you @ASCO @ASCOPost for giving us the opportunity to work on this important effort & to provide guidance in the care of patients living with NETs! https://t.co/sW35kXZ0QG
Congratulations to @jana_ivanidze on her contribution to the ASCO Guideline on Systemic Therapy for Tumor Control in Metastatic Well-Differentiated GEP-NETs, published in @JCO_ASCO!
Let’s Talk About NETs!!#NETCancerAwarenessDay
Check out our latest addition @ASCO Treatment Guidelines for the treatment of Well Diff. GEP NETS. Thank you to my mentors @rachnatshroff @ajscott40 @adasarimd @UAZHemeOnc @UAZCancer Chairs @JaydiDelRivero KimberlyPerez and other wonderful members. https://t.co/TbAZhM8IsF
All mentions
Symptom Management for Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors Guideline
Guidelines for Systemic Therapy in Metastatic GEP-NETs
Dr. Jaydira Del Rivero and Dr. Kimberly Perez discuss the ASCO guideline on systemic therapy for metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Key recommendations include somatostatin analogs as…
RT @jgong15: Highlighting seminal work from #KOL speakers at the 6th Annual @CSCancerCenter GI Tumor Conf: @AGangiMD: Tumor growth in stea…
RT @jgong15: Highlighting seminal work from #KOL speakers at the 6th Annual @CSCancerCenter GI Tumor Conf: @AGangiMD: Tumor growth in stea…
RT @jgong15: Highlighting seminal work from #KOL speakers at the 6th Annual @CSCancerCenter GI Tumor Conf: @AGangiMD: Tumor growth in stea…
RT @jgong15: Highlighting seminal work from #KOL speakers at the 6th Annual @CSCancerCenter GI Tumor Conf: @AGangiMD: Tumor growth in stea…
RT @jgong15: Highlighting seminal work from #KOL speakers at the 6th Annual @CSCancerCenter GI Tumor Conf: @AGangiMD: Tumor growth in stea…
RT @jgong15: Highlighting seminal work from #KOL speakers at the 6th Annual @CSCancerCenter GI Tumor Conf: @AGangiMD: Tumor growth in stea…
RT @jgong15: Highlighting seminal work from #KOL speakers at the 6th Annual @CSCancerCenter GI Tumor Conf: @AGangiMD: Tumor growth in stea…
Highlighting seminal work from #KOL speakers at the 6th Annual @CSCancerCenter GI Tumor Conf: @AGangiMD: Tumor growth in steatotic liver & #GEPNET @ASCO guidelines https://t.co/V1HIAIWjXn https://t.co/nRJLsaow8E April 5, 2025. Register at https://t.co/ygFRaIUvTJ @OncoAlert https://t.co/C1sfOBkM2d
RT @JaydiDelRivero: Truly grateful to be part of the first ASCO guideline for the management of NETs and everyone involved! Thank you @ASCO…
RT @JaydiDelRivero: Truly grateful to be part of the first ASCO guideline for the management of NETs and everyone involved! Thank you @ASCO…
RT @JaydiDelRivero: Truly grateful to be part of the first ASCO guideline for the management of NETs and everyone involved! Thank you @ASCO…
ちょうどASCOガイドラインの新しいものが出たばかり。こちらは症候性/高腫瘍量のpanNETにはCAPTEMを弱く推奨 https://t.co/5ZYPc61i1A https://t.co/aLzpKEmPjI
RT @JaydiDelRivero: Let’s Talk About NETs!!#NETCancerAwarenessDay
RT @JaydiDelRivero: Let’s Talk About NETs!!#NETCancerAwarenessDay
RT @JaydiDelRivero: Truly grateful to be part of the first ASCO guideline for the management of NETs and everyone involved! Thank you @ASCO…
RT @JaydiDelRivero: Truly grateful to be part of the first ASCO guideline for the management of NETs and everyone involved! Thank you @ASCO…
RT @JaydiDelRivero: Truly grateful to be part of the first ASCO guideline for the management of NETs and everyone involved! Thank you @ASCO…
RT @JaydiDelRivero: Let’s Talk About NETs!!#NETCancerAwarenessDay
RT @JaydiDelRivero: Truly grateful to be part of the first ASCO guideline for the management of NETs and everyone involved! Thank you @ASCO…
RT @JaydiDelRivero: Let’s Talk About NETs!!#NETCancerAwarenessDay
RT @JaydiDelRivero: Truly grateful to be part of the first ASCO guideline for the management of NETs and everyone involved! Thank you @ASCO…
Truly grateful to be part of the first ASCO guideline for the management of NETs and everyone involved! Thank you @ASCO @ASCOPost for giving us the opportunity to work on this important effort & to provide guidance in the care of patients living with NETs! https://t.co/sW35kXZ0QG
RT @JaydiDelRivero: Let’s Talk About NETs!!#NETCancerAwarenessDay
RT @JaydiDelRivero: Let’s Talk About NETs!!#NETCancerAwarenessDay
Let’s Talk About NETs!!#NETCancerAwarenessDay
Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline | Journal of Clinical Oncology https://t.co/2QxcHBjqd0
RT @JCO_ASCO: ICYMI: Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic #NeuroendocrineTumors: @AS…
RT @JCO_ASCO: ICYMI: Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic #NeuroendocrineTumors: @AS…
RT @JCO_ASCO: ICYMI: Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic #NeuroendocrineTumors: @AS…
RT @JCO_ASCO: ICYMI: Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic #NeuroendocrineTumors: @AS…
RT @JCO_ASCO: ICYMI: Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic #NeuroendocrineTumors: @AS…
RT @JCO_ASCO: ICYMI: Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic #NeuroendocrineTumors: @AS…
RT @JCO_ASCO: ICYMI: Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic #NeuroendocrineTumors: @AS…
RT @JCO_ASCO: ICYMI: Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic #NeuroendocrineTumors: @AS…
RT @JCO_ASCO: ICYMI: Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic #NeuroendocrineTumors: @AS…
ICYMI: Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic #NeuroendocrineTumors: @ASCO Guideline
RT @drkpavithran: Metastatic well-differentiated Gastroenteropancreatic NET- Systemic therapy ASCO guideline https://t.co/CO7cgyGDGN https:…
Metastatic well-differentiated Gastroenteropancreatic NET- Systemic therapy ASCO guideline https://t.co/CO7cgyGDGN https://t.co/bZqf6wLDDT
Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline https://t.co/w4DK5T8R2M
RT @Globeseek: https://t.co/1LELevIain nearly impossible to tag all that were involved, honored to have contributed @ASCO @JaydiDelRivero…
RT @drjunaidarsh: Check out our latest addition @ASCO Treatment Guidelines for the treatment of Well Diff. GEP NETS. Thank you to my mentor…
RT @NeuroendocrinoS: Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASC…
RT @dralanburguete: Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO…
Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline | Journal of Clinical Oncology https://t.co/XEwnS1t5IZ
Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline | Journal of Clinical Oncology https://t.co/5OpJ0hrFDC
Guías nuevas @ASCO sobre GEP-NET metastásico. https://t.co/1ae4MjOrZW
RT @net_connectinfo:
RT @MolecularWCM: Congratulations to @jana_ivanidze on her contribution to the ASCO Guideline on Systemic Therapy for Tumor Control in Met…
RT @net_connectinfo:
RT @net_connectinfo:
RT @drjunaidarsh: Check out our latest addition @ASCO Treatment Guidelines for the treatment of Well Diff. GEP NETS. Thank you to my mentor…
RT @Globeseek: https://t.co/1LELevIain nearly impossible to tag all that were involved, honored to have contributed @ASCO @JaydiDelRivero…
RT @MolecularWCM: Congratulations to @jana_ivanidze on her contribution to the ASCO Guideline on Systemic Therapy for Tumor Control in Met…
RT @net_connectinfo:
RT @drjunaidarsh: Check out our latest addition @ASCO Treatment Guidelines for the treatment of Well Diff. GEP NETS. Thank you to my mentor…
RT @MolecularWCM: Congratulations to @jana_ivanidze on her contribution to the ASCO Guideline on Systemic Therapy for Tumor Control in Met…
RT @MolecularWCM: Congratulations to @jana_ivanidze on her contribution to the ASCO Guideline on Systemic Therapy for Tumor Control in Met…
RT @MolecularWCM: Congratulations to @jana_ivanidze on her contribution to the ASCO Guideline on Systemic Therapy for Tumor Control in Met…
RT @MolecularWCM: Congratulations to @jana_ivanidze on her contribution to the ASCO Guideline on Systemic Therapy for Tumor Control in Met…
RT @MolecularWCM: Congratulations to @jana_ivanidze on her contribution to the ASCO Guideline on Systemic Therapy for Tumor Control in Met…
Congratulations to @jana_ivanidze on her contribution to the ASCO Guideline on Systemic Therapy for Tumor Control in Metastatic Well-Differentiated GEP-NETs, published in @JCO_ASCO!
RT @Globeseek: https://t.co/1LELevIain nearly impossible to tag all that were involved, honored to have contributed @ASCO @JaydiDelRivero…
Check out our latest addition @ASCO Treatment Guidelines for the treatment of Well Diff. GEP NETS. Thank you to my mentors @rachnatshroff @ajscott40 @adasarimd @UAZHemeOnc @UAZCancer Chairs @JaydiDelRivero KimberlyPerez and other wonderful members. https://t.co/TbAZhM8IsF
RT @Globeseek: https://t.co/1LELevIain nearly impossible to tag all that were involved, honored to have contributed @ASCO @JaydiDelRivero…
RT @Globeseek: https://t.co/1LELevIain nearly impossible to tag all that were involved, honored to have contributed @ASCO @JaydiDelRivero…
https://t.co/1LELevIain nearly impossible to tag all that were involved, honored to have contributed @ASCO @JaydiDelRivero @OncoThor @marklewismd glad that this was released this week as our friends all meet in Montreal for @NANETS1 symposium
RT @dr_yakupergun: Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO…
RT @dr_yakupergun: Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO…
RT @dr_yakupergun: Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO…
RT @dr_yakupergun: Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO…
RT @dr_yakupergun: Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO…
RT @dr_yakupergun: Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO…
RT @dr_yakupergun: Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO…
* https://t.co/cEyujO8cT0
RT @dr_yakupergun: Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO…
https://t.co/SAaxxwwg88
RT @dr_yakupergun: Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO…
RT @dr_yakupergun: Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO…
RT @dr_yakupergun: Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO…
RT @dr_yakupergun: Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO…
RT @dr_yakupergun: Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO…
RT @dr_yakupergun: Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO…
RT @dr_yakupergun: Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO…
RT @dr_yakupergun: Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO…
RT @dr_yakupergun: Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO…
RT @dr_yakupergun: Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO…
RT @dr_yakupergun: Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO…
RT @dr_yakupergun: Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO…
RT @dr_yakupergun: Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO…
RT @dr_yakupergun: Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO…
RT @dr_yakupergun: Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO…
RT @dr_yakupergun: Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO…
RT @dr_yakupergun: Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO…
RT @dr_yakupergun: Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO…
RT @dr_yakupergun: Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO…
RT @dr_yakupergun: Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO…
RT @dr_yakupergun: Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO…
RT @dr_yakupergun: Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO…
RT @dr_yakupergun: Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO…
RT @dr_yakupergun: Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO…
RT @dr_yakupergun: Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO…
RT @dr_yakupergun: Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO…
RT @dr_yakupergun: Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO…
♦️Systemic Therapy for Tumor Control in Metastatic Well-Differentiated GEP Neuroendocrine Tumors: ASCO Guideline update ➡️ SSA for first line ➡️ PRRT for second line ➡️ Chemo for certain cases @weoncologists #Medtwitter @JCO_ASCO https://t.co/XGc7S9rwYg
RT @dr_yakupergun: Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO…
RT @dr_yakupergun: Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO…
RT @dr_yakupergun: Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO…
RT @dr_yakupergun: Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO…
RT @dr_yakupergun: Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO…
RT @dr_yakupergun: Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO…
RT @dr_yakupergun: Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO…
RT @dr_yakupergun: Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO…
RT @dr_yakupergun: Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO…
RT @dr_yakupergun: Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO…
RT @dr_yakupergun: Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO…
RT @dr_yakupergun: Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO…
Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline